We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00381394
First Posted: September 27, 2006
Last Update Posted: September 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
GlaxoSmithKline
  Purpose
Sitamaquine is an 8-aminoquinoline which is being developed as an oral treatment for visceral leishmaniasis (VL). Pre-clinical and subsequent clinical investigations have demonstrated oral efficacy against Leishmania donovani. The purposes of this study are to characterise the pharmacokinetic profile of sitamaquine, administered orally, and to determine if the pharmacokinetic profile is affected by administration with food. The study is also designed to further characterise the safety and tolerability of sitamaquine compared with amphotericin B, particularly in reference to renal, hepatic and cardiac adverse events, prior to initiation of phase III studies. Finally the study will investigate the efficacy of a 21 day treatment course. Previous studies have used 28 days dosing, but parasitological evidence from one study suggests that shorter courses may be effective.

Condition Intervention Phase
Leishmaniasis, Visceral Drug: sitamaquine Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-centre, Open-label, Randomised Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Sitamaquine Compared With Amphotericin B in the Treatment of Visceral Leishmaniasis Caused by L. Donovani in Endemic Areas.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Area under the concentration-time curve over the dosing interval AUC(0-tau) for sitamaquine [ Time Frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose ]
    AUC is defined as the area under the concentration-time curve from 0 to last quantifiable concentration (AUC 0-tau). AUC is a measure of exposure. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21. Only those participants with data available at the specified time points were analyzed.

  • Maximum plasma concentration (Cmax) for sitamaquine [ Time Frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. ]
    Cmax was defined as the maximum concentration of sitamaquine. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21.

  • Time to maximum observed plasma concentration (tmax) for sitamaquine [ Time Frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. ]
    Tmax is defined as the time to peak concentration from initiation of sitamaquine dosing. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21.

  • Accumulation ratio for sitamaquine [ Time Frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose ]
    Point estimate was the ratio of adjusted geometric means between repeat dosing days (Day 21 or Day 10) and single dose day (Day 1). An evaluation on the accumulation rate was based upon the comparison of AUC(0-24) values after repeated dosing to the values from the first dose on day 1. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21. Individual observed accumulation ratios on Day 10 were calculated by dividing AUC (0-tau) on Day 10 by AUC (0-tau) on Day 1. A similar formula was applied to the accumulation ratio on Day 21.


Secondary Outcome Measures:
  • Number of participants with adverse events(AEs) and serious adverse events(SAEs) [ Time Frame: Up to 180 days ]
    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Data for on-treatment AEs have been reported,

  • Number of participants with abnormal 12-lead Electrocardiogram (ECG) values [ Time Frame: At Day 22 for Sitamaquine and Day 31 for Amphotericin B ]
    Data for abnormal findings have been reported at Day 22 for Sitamaquine and Day 31 for Amphotericin B. All ECGs were collected in the supine position with the electrodes placed in the standard positions, 4 hours after dosing on drug administration days, and prior to blood collection or pulse rate measurement.

  • Number of participants with abnormal echocardiography results [ Time Frame: Up to Day 22 and 49 (sitamaquine only) and Day 31 and 58 (amphotericin B only) ]
    2-D echocardiograms were performed at screening (all participants), Days 22 and 49 (sitamaquine only) and days 31 and 58 (amphotericin B only). All echocardiograms were obtained after the participant has rested in a semi-supine position for at least 10 minutes. All echocardiograms were stored electronically (e.g video home system [VHS] tape, optical drive, etc.). Ejection fraction was estimated using the modified Simpson's rule method. Data for number of participants with abnormal echocardiography results have been reported.

  • Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at Day 180 [ Time Frame: Baseline (Day 1 pre-dose) and Day 180 ]
    Blood pressure (SBP and DBP) was recorded after the participant had rested in a semi-supine position for at least 10 minutes. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was Day 1 pre-dose.

  • Change from Baseline in heart rate [ Time Frame: Baseline (Day 1 pre-dose) and Day 180 ]
    Heart rate was recorded after the participant had rested in a semi-supine position for at least 10 minutes. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was Day 1 pre-dose.

  • Change from Baseline in body temperature [ Time Frame: Baseline (Day 1 pre-dose) and Day 180 ]
    Body temperature was recorded after the participant had rested in a semi-supine position for at least 10 minutes. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was Day 1 pre-dose.

  • Change from Baseline in body weight [ Time Frame: Baseline (Day 1 pre-dose) and Day 49 for Sitamaquine and Day 58 for Amphotericin B ]
    Body weight was recorded after the participant had rested in a semi-supine position for at least 10 minutes. Change from Baseline was calculated as any post-Baseline value minus the Baseline value. Baseline visit was Day 1 pre-dose.

  • Number of participants with abnormal hematology values at the end of study (Day 180) [ Time Frame: Day 180 ]
    Data for number of participants with hematology abnormalities for the end of study (Day 180) is presented. Hematology abnormalities were classified using Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grades and grade 3 ranges are as follows (selected): Hemoglobin (grams per liter [G/L])- <80 - 65; Total Neutrophils (gram international units per liter[GI/L])- <1.0 - 0.5 x 10^9/L; Platelet count(GI/L) <50.0- 25.0 x 10^9 /L; White Blood Cell (WBC) (GI/L)- <2.0 - 1.0 x 10^9 /L. Data only for categories with values have been presented.

  • Number of participants with abnormal clinical chemistry values at the end of study (Day 180) [ Time Frame: Day 180 ]
    Aspartate Amino Transferase (AST) ([international units per liter [IU/L])- >5.0 - 20.0 x upper limit of normal (ULN); Albumin(G/L)- <20 g/dL; Alkaline Phosphatase(IU/L)- >5.0 - 20.0 x ULN; Alanine Amino Transferase(IU/L)- >5.0 - 20.0 x ULN; Total Bilirubin( micromoles per liter [µMOL/L])- >3.0 - 10.0 x ULN; Urea(millimoles per liter [MMOL/L])- 5.1 - 10 x ULN; Cholesterol (MMOL/L) - >10.34 - 12.92; Creatine Kinase MB (microgram per liter[µ/L])->5 x ULN - 10 x ULN; Creatinine Clearance(milliliter per minute [mL/min])- <25% lower limit of normal (LLN); Creatinine(µMOL/L)- >3.0 - 6.0 x ULN; Gamma Glutamyl Transferase(IU/L)- >5.0 - 20.0 x ULN; Potassium(MMOL/L)- >6.0 - 7.0(high) and <3.0 - 2.5 (low); Sodium(MMOL/L)- >155 - 160; Sodium(MMOL/L)- <130 - 120; Triglycerides(MMOL/L)- >5.0 - 10.0 x ULN. Data only for categories with values have been presented.

  • Number of participants with Initial parasitological cure (28 days) [ Time Frame: Up to 28 days ]
    Initial parasitological cure was defined as a parasite-negative splenic aspirate at completion of treatment or, if the leishmania index (a quantitative assessment of parasites in the splenic aspirate) was +1, a parasite-negative result at the repeat splenic aspirate 28 days later.

  • Number of participants with Final parasitological cure (6 months) [ Time Frame: Up to 180 days ]
    Final clinical cure was defined as initial parasitological cure (initial parasitological cure was defined as a parasite-negative splenic aspirate at completion of treatment or, if the leishmania index [a quantitative assessment of parasites in the splenic aspirate] was +1, a parasite-negative result at the repeat splenic aspirate 28 days later) and no evidence of relapse at 6 months.

  • Terminal elimination half-life (t1/2) for sitamaquine [ Time Frame: At Day 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose ]
    Half life is defined as the period of time required for the amount of drug in the body to be reduced by half. Blood samples for determination of plasma concentrations of sitamaquine was obtained at the following time points on days 1, 10 and 21: immediately pre-dose, and at 1, 2, 3, 4, 6, 10, 16 hours post dose. An additional sample was taken on Day 23 and Day 24 to approximate 48 hours and 72 hours post last dose on Day 21.


Enrollment: 61
Actual Study Start Date: August 4, 2006
Study Completion Date: September 14, 2007
Primary Completion Date: September 14, 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Clinical diagnosis of visceral leishmaniasis; symptoms and signs compatible with VL and diagnosis confirmed by visualisation of amastigotes in splenic aspirate or bone marrow.
  • Written informed consent or witnessed oral consent.
  • Willing to comply with the study visits and procedures.
  • For female subjects, a negative urine pregnancy test at screening and before dosing and the subject agrees to use an established method of birth control (including abstinence).

Exclusion criteria:

  • Past history of renal disease or impaired renal function at screening.
  • History of any significant hepatic or biliary disease, or the following abnormal laboratory values at screening; hepatic dysfunction (AST or ALT 2.5 times upper limit of normal).
  • Subjects with the following abnormal laboratory values; haemoglobin 6.5 g/dl, neutrophils <750/ mm3, platelets <50,000 / mm3, any clinically relevant abnormality identified on screening examination or clinical laboratories which would preclude the subject's safe participation in the study.
  • History of cardiac disease, arrhythmias, conduction abnormalities or any clinically relevant abnormality identified on 12-lead ECG at screening.

Subjects suffering from a concomitant infection, blood disorder or any other serious underlying disease which would preclude evaluation of the subject's response to the study medication.

Methaemoglobin levels >5% at screening. G6PD deficiency.

  • Positive HIV antibody, hepatitis B surface antigen or hepatitis C antibody at screening.
  • Pregnant or nursing women; women of childbearing potential who are unwilling or unable to use an appropriate form of contraception, from prior to study medication administration until 2 weeks following the last dose of investigational product.
  • Any contraindication to splenic aspirate (or bone marrow aspirate), including but not limited to PT prolonged >3 seconds longer than control or platelets <50,000 / mm3.
  • Subjects with a known hypersensitivity reaction to 8-aminoquinolines (e.g. primaquine) or any of the investigational product excipients.
  • Treatment with an established antileishmanial chemotherapeutic agent within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  • Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00381394


Locations
India
GSK Investigational Site
Muzaffarpur, India, 842001
GSK Investigational Site
Muzaffarpur, India
GSK Investigational Site
Patna, India, 800007
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications:
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00381394     History of Changes
Other Study ID Numbers: STQ105938
First Submitted: September 26, 2006
First Posted: September 27, 2006
Last Update Posted: September 18, 2017
Last Verified: September 2017

Keywords provided by GlaxoSmithKline:
amphotericin B
safety
tolerability and pharmacokinetics of oral sitamaquine
Visceral leishmaniasis

Additional relevant MeSH terms:
Leishmaniasis
Leishmaniasis, Visceral
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases
Skin Diseases, Parasitic
Skin Diseases, Infectious
Skin Diseases
Amphotericin B
Liposomal amphotericin B
Amebicides
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Bacterial Agents
Antifungal Agents